Restatement of Previously Issued Financial Statements - Restatement of Consolidated Statement of Cash Flows (Details) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)		$ (54,090,319)	$ (2,080,958)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued by licensee to subsidiary in payment of services		$ (192,000)
Stock issued for services rendered by consultants			$ 26,180
Stock issued for interest			3,570
Stock issued for expenses			$ 48,000
Interest Expense attributable to amortization of discount		$ 150,806
Impairment on Available for Sale Securities		41,333,361
Additional paid in Capital		1,010,650	$ 300,000
Loss on Settlement of Debt through Equity Issuance		10,133,872	$ 1,112,230
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses		(10,000)
Increase (Decrease) in Accounts Payable		9,484	$ 19,920
Increase (Decrease) in Accrued Expenses		207,624	12,397
Increase (Decrease) in bank Overdraft		(6,137)	6,137
(Increase) Decrease in Interest Receivable		$ (1,148)	(233)
Increase (Decrease) in Due to Affiliate			(34,895)
(Increase) Decrease in Note Receivable		$ (1,629)	(10,422)
Net Cash Provided by (Used in) Operating Activities		$ (1,455,436)	(598,074)
CASH FLOWS FROM FINANCING ACTIVITIES
Preferred Stock issued for Cash			$ 100,000
Common Stock issued for Cash	$ 50,000
Stock in subsidiary sold for cash		$ 50,000
Principal borrowings (repayments) on notes and Convertible Debentures		206,603	$ 316,862
Principal borrowings (repayments) on Convertible Debentures		$ 1,272,686
(Increase) Decrease in Deferred Financing Costs			$ 65,000
Net Cash Provided by (Used in) Financing Activities		$ 1,531,289	481,862
Net Increase (Decrease) in Cash		75,853	(116,212)
Cash at Beginning of Period		502	116,714
Cash at End of Period	76,355	76,355	502
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt		157,500	$ 158,000
Common Shares of Regen Biopharma, Inc. Issued for Debt		1,002,686
As Originally Reported
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)		(12,756,958)	$ (2,080,958)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued by licensee to subsidiary in payment of services		(192,000)
Stock issued for services rendered by consultants			26,180
Stock issued for interest			3,570
Stock issued for expenses			48,000
Interest Expense attributable to amortization of discount		$ 150,806
Impairment on Available for Sale Securities
Additional paid in Capital
Loss on Settlement of Debt through Equity Issuance
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses		$ (10,000)
Increase (Decrease) in Accounts Payable		9,484
Increase (Decrease) in Accrued Expenses		207,624
Increase (Decrease) in bank Overdraft		(6,137)
(Increase) Decrease in Interest Receivable		$ (1,148)
Increase (Decrease) in Due to Affiliate
(Increase) Decrease in Note Receivable		$ (1,629)
Net Cash Provided by (Used in) Operating Activities		(12,599,958)
CASH FLOWS FROM FINANCING ACTIVITIES
Preferred Stock issued for Cash			100,000
Additional Paid in Capital		1,010,650	300,000
Increase (Decrease) in due to shareholder		0
Stock in subsidiary sold for cash		50,000
Principal borrowings (repayments) on notes and Convertible Debentures		208,603	316,862
Principal borrowings (repayments) on Convertible Debentures		$ 1,272,686
(Increase) Decrease in Deferred Financing Costs			65,000
Loss on Settlement of Debt through Equity Issuance			1,112,230
Net Cash Provided by (Used in) Financing Activities		$ 12,675,811	1,894,092
Net Increase (Decrease) in Cash		75,853	(116,212)
Cash at Beginning of Period		502	116,714
Cash at End of Period	76,355	76,355	502
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt		157,500	158,000
Common Shares of Regen Biopharma, Inc. Issued for Debt		1,002,686
Cash paid for Interest		0	0
Cash paid for Income Tax		0	0
Adjustments
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)		(41,333,361)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Impairment on Available for Sale Securities		41,333,361
Additional paid in Capital		1,010,650
Loss on Settlement of Debt through Equity Issuance		10,133,872
Changes in operating assets and liabilities:
Net Cash Provided by (Used in) Operating Activities		11,144,522
CASH FLOWS FROM FINANCING ACTIVITIES
Additional Paid in Capital		(1,010,650)	(300,000)
Loss on Settlement of Debt through Equity Issuance		10,133,872	(1,112,230)
Net Cash Provided by (Used in) Financing Activities		(11,143,982)	(1,412,230)
Restated
CASH FLOWS FROM OPERATING ACTIVITIES
NET INCOME (LOSS)		(54,090,319)	(2,080,958)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued by licensee to subsidiary in payment of services		(192,000)
Stock issued for services rendered by consultants			26,180
Stock issued for interest			3,570
Stock issued for expenses			48,000
Interest Expense attributable to amortization of discount		150,806
Impairment on Available for Sale Securities		41,333,361
Additional paid in Capital		1,010,650	$ 300,000
Loss on Settlement of Debt through Equity Issuance		10,133,872
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses		(10,000)
Increase (Decrease) in Accounts Payable		9,484	$ 19,920
Increase (Decrease) in Accrued Expenses		207,624	12,397
Increase (Decrease) in bank Overdraft		(6,137)	6,137
(Increase) Decrease in Interest Receivable		$ (1,148)	(233)
Increase (Decrease) in Due to Affiliate			(34,895)
(Increase) Decrease in Note Receivable		$ (1,629)	(10,422)
Net Cash Provided by (Used in) Operating Activities		(1,455,436)	(598,074)
CASH FLOWS FROM FINANCING ACTIVITIES
Preferred Stock issued for Cash			100,000
Additional Paid in Capital		0	$ 0
Stock in subsidiary sold for cash		50,000
Principal borrowings (repayments) on notes and Convertible Debentures		208,603	$ 316,862
Principal borrowings (repayments) on Convertible Debentures		$ 1,272,686
(Increase) Decrease in Deferred Financing Costs			$ 65,000
Loss on Settlement of Debt through Equity Issuance		$ 10,133,872	0
Net Cash Provided by (Used in) Financing Activities		1,531,289	481,862
Net Increase (Decrease) in Cash		75,853	(116,212)
Cash at Beginning of Period		502	116,714
Cash at End of Period	$ 76,355	76,355	502
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt		157,500	$ 158,000
Common Shares of Regen Biopharma, Inc. Issued for Debt		1,002,686
Cash paid for Interest		0	$ 0
Cash paid for Income Tax		$ 0	$ 0